CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $382, high $743, with mid-point at $561.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$561
Margin of safety
+48.5%
Confidence
83/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$289.07Price
Low $382.18
Mid $561.36
High $742.98
CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Evernorth scale and specialty pharmacy
Evernorth scale and specialty pharmacy dominance
Vertical integration of PBM and
Vertical integration of PBM and health benefits
Cycle upside
Consolidation of specialty pharmacy and managed care services driving scale efficiencies.
§2 Caso bajista
Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.
Cómo puede fallar esta tesis
PBM Spread Pricing Ban
· High
Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.
FV impact
Moderate to Severe
Trigger
12-24 months
Medical Cost Spike
· Medium
Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.
FV impact
Moderate
Trigger
6-12 months
De-leveraging Failure
· Low
Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.
FV impact
Severe
Trigger
24-36 months
Señales de alerta temprana a vigilar
Métrica
Actual
Umbral de activación
Operating margins sustainably compressing toward the 3.0% industry median over 4 consecutive quarters.
Monitor
Deterioration versus the report thesis
Total corporate revenue actively dropping into negative YoY growth territory.
Monitor
Deterioration versus the report thesis
Unplanned suspension of the share repurchase program.
Monitor
Deterioration versus the report thesis
Medical care ratio (MCR) exceeding internal targets for two consecutive quarters.
Monitor
Deterioration versus the report thesis
Key enterprise client losses within the Evernorth segment.
Based on our latest analysis, CI looks meaningfully undervalued. The current price is $289 versus a composite fair-value midpoint of $561 (range $382–$743), which implies roughly 94.2% upside to the midpoint.
Our composite fair-value range for CI is $382–$743, with a midpoint of $561. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for CI's archetype.
Our current rating for CI is Strong Buy with a confidence score of 83/100. CI is rated Strong Buy at $289.07 versus the reconciled fair value midpoint of $561.36, implying +94.20% upside/downside. Confidence is separately disclosed at 83/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for CI are: PBM Spread Pricing Ban; Medical Cost Spike; De-leveraging Failure. The single biggest risk is PBM Spread Pricing Ban: Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.
Our current rating for CI is Strong Buy, issued with a confidence score of 83/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($382–$743) versus the current price of $289.
CI is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for CI.
